2. Participants disposition.
| Studies | Intervention(s)/ Comparator(s) | Randomised (N) | Received treatment (N) | Discontinued treatment (N) | Efficacy analysis (N) | Safety analysis (N) |
| Eichelberg 2015 | Soreafenib/ Sunitinib | 182 | 177 | 161 | 182 | 177 |
| Sunitinib/ Sorafenib | 183 | 176 | 156 | 183 | 176 | |
| Escudier 2010 | Bevacizumab + IFN‐a2a | 327 | 325 | 206 | 327 | 337 |
| IFN‐a2a + Placebo | 322 | 316 | 274 | 322 | 304 | |
| Escudier 2017 1 | Sunitinib | 546 | 535 | 438 | 546 | 535 |
| Nivolumab + Ipilimumab | 550 | 547 | 419 | 550 | 547 | |
| Hudes 2007 | Temsirolimus | 209 | 208 | 199 | 209 | 208 |
| Temsirolimus + Interferon | 210 | 208 | 193 | 210 | 208 | |
| Interferon | 207 | 200 | 194 | 207 | 200 | |
| McDermott 2017 | Sunitinib | 101 | 100 | 83 | 101 | 100 |
| Atezolizumab + Bevacizumab | 101 | 101 | 69 | 101 | 101 | |
| Atezolizumab | 103 | 103 | 80 | 103 | 103 | |
| Motzer 2010 | Sunitinib | 375 | 375 | 127 | 375 | 375 |
| IFN‐a2a | 375 | 360 | 234 | 375 | 360 | |
| Motzer 2013a | Pazopanib | 557 | 554 | 486 | 557 | 554 |
| Sunitinib | 553 | 548 | 483 | 553 | 548 | |
| Motzer 2013b | Tivozanib | 260 | 259 | 154 | 260 | 259 |
| Sorafenib | 257 | 257 | 192 | 257 | 257 | |
| Motzer 2014 | Sunitinib/ Everolimus | 233 | 231 | 192 | 233 | 231 |
| Everolimus/ Sunitinib | 238 | 238 | 201 | 238 | 238 | |
| Motzer 2019 | Sunitinib | 444 | 439 | 227 | 444 | 439 |
| Avelumab + Axitinib | 442 | 434 | 187 | 442 | 434 | |
| Ravaud 2015 | Everolimus + Bevacizumab | 182 | 180 | 175 | 182 | 180 |
| Interferon + Bevacizumab | 183 | 181 | 175 | 183 | 181 | |
| Retz 2019 | Sorafenib/ Pazopanib | 189 | 183 | 115 | 189 | 183 |
| Pazopanib/ Sorafenib | 188 | 183 | 110 | 188 | 183 | |
| Rini 2008 | Bevacizumab + IFN‐a2b | 369 | 366 | 355 | 369 | 366 |
| IFN‐a2b | 363 | 350 | 355 | 363 | 349 | |
| Rini 2014 | Temsirolimus + Bevacizumab | 400 | 393 | 372 | 400 | 393 |
| Temsirolimus + Interferon | 391 | 391 | 354 | 391 | 391 | |
| Rini 2016 | Sunitinib | 135 | 130 | 23 | 135 | 132 |
| IMA901 + Sunitinib | 204 | 185 | 28 | 204 | 202 | |
| Rini 2019a | Sunitinib | 429 | 425 | 242 | 429 | 425 |
| Pembrolizumab + Axitinib | 432 | 429 | 176 | 432 | 429 | |
| Rini 2019b | Sunitinib | 461 | 446 | 308 | 461 | 446 |
| Atezolizumab + Bevacizumab | 454 | 451 | 265 | 454 | 451 | |
| Sternberg 2010 | Pazopanib | 290 | 290 | 227 | 290 | 290 |
| Placebo | 145 | 145 | 131 | 145 | 145 | |
| Total | 11590 | 11419 | 8366 | 11590 | 11437 | |
1 Included overall population; but in the data and analyses section and summary of findings table, we used IMDC intermediate and poor risk patients for efficacy analysis.